Hikma Pharmaceuticals PLC Share Price and Company Fundamentals
Last traded: Today at 7:12 PM
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Key Metrics
PE ratio
8.96
PB ratio
137.51
Dividend yield
5.12%
Beta
0.65
Market cap
£2.82B
Enterprise value
£4.07B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Full time employees | 9400 |
| Website | https://www.hikma.com |
| Mailing address | 1 New Burlington Place London W1S 2HR United Kingdom |
| Phone / Fax | 44 20 7399 2760 / |
Dividends
Dividend yield
5.12%
Dividend amount
£0.62
Payout ratio
46.49%
5Y Avg. yield
-%
Hikma Pharmaceuticals PLC paid £0.62 dividend and the ex-dividend date was 19 Mar 2026.The dividend payout ratio is 46.49%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.HIK dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Mar 2026, following are the company executives and directors listed on Hikma Pharmaceuticals PLC.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| H.E Said Samih Taleb Darwazah | Chief Executive Officer | 68 | |
| Mr. Mazen Samih Taleb Darwazah | Executive Vice Chairman, President of MENA & Deputy CEO of MENA | 67 | |
| Mr. Areb AL KURDI | VP, Group Financial Controller & Acting CFO | 51 | |
| Patricia Bousfield | Chief Information Officer | ||
| Mr. Guy Featherstone | Associate Director of Investor Relations | ||
| Mr. Samuel Park | General Counsel | ||
| Mr. Bassam Wael Rushdi Kanaan CFA, CPA | Executive Vice President of Corporate Development and M&A | 60 | |
| Mr. Hussein Omar Arkhagha | Chief People Officer | ||
| Ms. Susan Ringdal | Executive Vice President of Strategic Planning & Global Affairs | ||
| Ms. Julie Hill | Senior Vice President of Corporate Quality Compliance/Health & Safety |
Profitability and management effectiveness
Profit margin
12.00%
Operating margin
14.84%
Return on assets
7.23%
Return on equity
16.52%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Hikma Pharmaceuticals PLC is 2.82B and its enterprise value is 4.07B. The enterprise value to revenue ratio of HIK is 1.22. The enterprise value to EBITDA ratio of HIK is 4.97.
The HIK's stocks Beta value is 0.65 making it 35% less volatile compared to LSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Hikma Pharmaceuticals PLC (LSE:HIK) Frequently Asked Questions
1. What is Hikma Pharmaceuticals PLC's Stock Symbol?
Hikma Pharmaceuticals PLC trades on LSE under the ticker symbol "HIK".
2. What is Hikma Pharmaceuticals PLC's stock price today?
One share of HIK stock can currently be purchased for approximately £1209.
3. How can I contact Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC's mailing address is 1 New Burlington Place London W1S 2HR United Kingdom. The company can be reached via phone at 44 20 7399 2760.
4. What is Hikma Pharmaceuticals PLC's official website?
The official website of Hikma Pharmaceuticals PLC is https://www.hikma.com.